MedTrace Logo

Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.

NCT05258877 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-11-21

No results posted yet for this study

Summary

To determine the pharmacokinetics of ethionamide (Eto) and ethionamide-sulfoxide (Eto-SO) in participants with tuberculosis (TB) when Eto is dosed under programmatic conditions.

Conditions

  • Tuberculosis, Pulmonary

Interventions

OTHER

Plasma samples

Up to 80ml of plasma may be collected from each participant over the 24 hour sampling period to be used for PK analysis.

Sponsors & Collaborators

  • TASK Applied Science

    collaborator OTHER

  • BioVersys AG

    lead INDUSTRY

Principal Investigators

  • Glenn Dale · BioVersys AG

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2023-09-28
Completion
2023-09-30

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258877 on ClinicalTrials.gov